Executive leadership at 89bio.
Research analysts covering 89bio.
Recent press releases and 8-K filings for ETNB.
89bio to be Acquired by Roche
ETNB
M&A
Takeover Bid
- 89bio, Inc. announced an agreement to be acquired by Roche for up to $20.50 per share in cash, comprising $14.50 per share at closing and a non-tradeable contingent value right (CVR) for up to an additional $6.00 per share.
- The transaction represents a total equity value of up to approximately $3.5 billion and a premium of approximately 79% to 89bio's closing stock price on September 17, 2025.
- The CVR payments are contingent upon achieving specific milestones: $2.00 per share for the first commercial sale of pegozafermin in F4 MASH cirrhotic patients by March 31, 2030; $1.50 per share for global annual net sales of at least $3.0 billion by December 31, 2033; and $2.50 per share for global annual net sales of at least $4.0 billion by December 31, 2035.
- The tender offer is expected to commence no later than October 1, 2025, and the transaction is anticipated to close in the fourth quarter of 2025.
Sep 18, 2025, 10:08 AM
89bio Provides Update on Pegosafirmin Clinical Development and Market Strategy
ETNB
New Projects/Investments
- 89bio's lead asset, pegosafirmin, is advancing in its Phase 3 ENLIGHTEN study for NASH (F2/F3 fibrosis and F4 cirrhosis), with over 250 sites activated across 20+ countries.
- Pegosafirmin is positioned as a differentiated FGF21 with the best relative risk reduction in fibrosis benefit among competitors, lower GI events, and potential for once-every-two-weeks dosing and GLP-1 co-formulation.
- The company anticipates results in Q1 2026 for its fully enrolled study in Severe Hypertriglyceridemia (SHTG), with plans to file it as a supplemental BLA.
- 89bio is exploring additional indications for pegosafirmin, such as other liver cirrhosis conditions and various fibrotic diseases, and is open to partnerships to support these efforts.
Sep 3, 2025, 4:36 PM
Recent SEC filings and earnings call transcripts for ETNB.
No recent filings or transcripts found for ETNB.